MAGEA9 is frequently overexpressed in bladder cancer, cutaneous T-cell lymphomas, oesophageal adenocarcinomas, as well as in renal cell carcinoma [51,52,53,54]. Here, MAGEA9 is linked to urinary bladder carcinoma.